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DOI: 10.1039/c2md20113eNovel primaquine derivatives, obtained by conjugation of the drug’s aliphatic amine with different
cinnamic acids, resulted in increased in vitro activity, compared to primaquine, against liver-stage
malarial parasites. The compounds were non-cytotoxic to human hepatoma cells, suggesting that they
are a promising new class of agents for the treatment and prevention of malaria.Effective and safe antimalarial drugs active against both liver
and erythrocytic parasite stages will be valuable components of
malaria eradication strategies.1 Mammalian infection by malar-
ial parasites is initiated by an infected mosquito bite, followed by
a clinically silent liver-stage infection, during which thousands of
merozoites are formed to be released into the bloodstream and
trigger the clinically relevant erythrocytic stage of the life cycle.2
Drugs able to act on the liver stage are highly relevant, as they
can be used in chemoprophylaxis to prevent all clinical mani-
festations of malaria.3 Moreover, such drugs are particularly
relevant in P. vivax and P. ovale infections, as in these species
latent forms that are called hypnozoites are not eliminated by
most available therapies, persist in the liver for long periods, and
subsequently cause malaria relapses. At present, drugs acting
against parasite liver forms are scarce, and primaquine (PQ, 1 in
Scheme 1) remains the only drug in clinical use that acts against
liver stages of all Plasmodium species,4 including P. vivax and
P. ovale hypnozoites.5 Unfortunately, PQ’s low oral bioavail-
ability and high hemotoxicity hold back its clinical use, especially
in vulnerable populations including pregnant women, infants
and the elderly. In addition, PQ causes hemolysis in patients with
congenital deficiency of glucose-6-phosphate dehydrogenase,5
complicating its use to treat P. vivax and P. ovale malaria and
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approaches to mask the PQ aliphatic amine in order to obtain
analogues resistant to oxidative deamination, the major meta-
bolic pathway underlying the drug’s low oral bioavailability
(Scheme 1) by conversion into an inactive metabolite, carboxy-
primaquine (2 in Scheme 1).5 To this end, we have successfully
developed imidazoquines (3 in Scheme 1)6,7 and primacenes (4 in
Scheme 1),8,9 peptidomimetic and organometallic derivatives of
PQ with promising antimalarial properties, respectively. Now,
we disclose a new family of PQ derivatives, the PRIMACINS (5
in Scheme 1), obtained by coupling PQ to cinnamic acids, as the
latter was formerly reported to possess interesting antimalarial
properties.10 PRIMACINS were found to have higher in vitro
activity than PQ against the liver-stage of the rodent malarial
parasite P. berghei (Fig. 1).
PRIMACINS were tested against liver stages of the rodent
parasite P. berghei and against erythrocytic stages of the human
parasite P. falciparum (Table 1). Compounds 5 were two- or
more-fold more potent than PQ against liver stage P. berghei and
were non-toxic to Huh7 human hepatoma cells in vitro, as shown
by cell confluency analysis (Fig. 1). The activities present a
relatively short activity range (1.38–2.39 mM), so any discussion
on structure–activity relationships based on the IC50 values
obtained would be of no significance. Furthermore, given that
the mechanisms of action of PQ against liver-stage parasites are
still poorly understood,5 it is always risky to attempt a justifi-
cation for activity trends observed, if any. Anyway, lipophilicity
may have had some influence on compound’s activity, as the two
most active compounds, 5h and 5c, were also the ones presenting
higher log P values, 5.77 and 6.15,12 respectively.
Regarding erythrocytic-stage activity, 5c was the only
compound that displayed an IC50 below 10 mM of the eleven
compounds 5, which was nevertheless one order of magnitude
higher than that of the reference erythrocytic-stage drug, arte-
misinin. The broad inactivity of compounds 5 against erythro-
cytic-stage parasites was not particularly surprising, as (i) PQ is
itself a modest blood-schizontocidal5 and (ii) compounds 5 lack aThis journal is ª The Royal Society of Chemistry 2012
Scheme 1 Chemical structures of primaquine (1), its main metabolite, carboxyprimaquine (2), PQ derivatives formerly developed by us, namely,
imidazoquines (3)6,7 and primacenes (4),8,9 and PRIMACINS herein reported (5): (i) PQ was coupled to cinnamic acids in the presence of 1.1 molar
equivalents (eq.) of TBTU and 2 eq. of N-ethyl-N,N-diisopropylamine, at room temperature for 24 h, using N,N-dimethylformamide as solvent.basic amine: the relevance of a basic amino group linked to the 8-
aminoquinoline core through a chain of two to six carbons for
the activity of PQ against erythrocytic Plasmodia was established
three decades ago.5,13,14 In fact, more recent well-known PQ
derivatives displaying some erythrocytic-stage activity have the
PQ’s basic aliphatic chain either conserved (e.g., tafenoquine) or
modified in a way that reasonably preserves its basicity (e.g.,
bulaquine and sitamaquine).5 Compared to other cinnamic
derivatives, which present low mM activities against Pf Dd2 and
W2 strains,10,15 combining the cinnamic moiety with PQ clearly
led to a loss of erythrocytic-stage activity. This suggests that theFig. 1 Activity of PRIMACINS 5 against P. berghei liver stages. Anti-infe
confluency scale, circles) are shown. Primaquine (1) at 10 mMwas included fo
were determined by bioluminescence measurements of cell lysates 48 h after
This journal is ª The Royal Society of Chemistry 2012lack of compounds 5 activity is due to the presence of the 8-
aminoquinoline pharmacophore and supports that the absence
of the aforesaid aliphatic amine is detrimental for inhibitory
erythrocytic activity of PQ derivatives.
As shown here, the absence of the aforementioned aliphatic
amine did not preclude the significant activity of PRIMACINS 5
against liver-stage Plasmodia. This result agrees with our
previous findings on PQ derivatives 4, as these organometallic
compounds were also highly active against liver-stage parasites,
regardless of whether a basic aliphatic amine group was present.
Yet, compounds 4 which lacked a basic aliphatic amine groupctive activity (infection scale, bars) and toxicity to hepatoma cells (cell
r comparison. Infection loads of Huh7 cells, a human hepatoma cell line,
infection with luciferase-expressing P. berghei parasites.11
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Table 1 Antiplasmodial activities of compounds 5
Compound R
IC50  SD (mM)
against liver-stage
P. berghei
IC50 (mM) against
erythrocytic-stage
P. falciparuma
Reference drugb — 7.50 (PQ) 5.64 nM (ART)
5a H 2.01  0.27 $10
5b p-Me 2.13  0.58 $10
5c p-iPr 1.54  0.35 4.84
5d p-OMe 2.35  0.19 $10
5e m-F 1.63  0.16 $10
5f p-F 2.33  0.47 $10
5g p-Cl 2.39  0.19 $10
5h p-Br 1.38  0.33 $10
5i o-NO2 2.36  0.58 $10
5j m-NO2 2.12  0.49 $10
5k p-NO2 2.24  0.27 $10
a Chloroquine-resistant strain W2. b PQ for liver-stage activity assays;
artemisinin (ART) for erythrocytic-stage activity assays.were inactive both against erythrocytic-stage parasites and as
transmission-blocking agents.8,9Concluding remarks
Novel primaquine derivatives, PRIMACINS 5, have been
synthesized through a cheap and simple one-step condensation
of the parent antimalarial drug with a series of cinnamic acids.
The compounds were screened in vitro for their activity against
two major stages of malarial infection in the mammalian host,
the liver- and the erythrocytic-stage, and found to have about
two- or more-fold higher potency than the parent drug against
liver parasites while non-toxic to human hepatoma cells.
Masking the aliphatic amine group of primaquine through
conjugation with the cinnamic moiety impairs the metabolic
oxidative deamination that underlies its low oral bioavailability,
which in turn requires administration of high doses of this
hemotoxic antimalarial drug. Thus, PRIMACINS represent a
new class of compounds toward the development of more
effective and potentially safer liver-stage active primaquine
derivatives.
To the best of our knowledge, this is an unprecedented
disclosure of primaquine–cinnamic acid conjugates as antima-
larial leads.1172 | Med. Chem. Commun., 2012, 3, 1170–1172Acknowledgements
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